Introduction
============

Lung cancer is among the most common malignant tumors and has increasing rates of morbidity and mortality worldwide ([@b1-ol-0-0-10373]). It is estimated that \~234,000 new lung cancer cases were diagnosed in 2018 in the United States, and that \~154,000 people will succumb to lung cancer in this year ([@b2-ol-0-0-10373]). The majority of patients with lung cancer (85%) are diagnosed with non-small cell lung cancer (NSCLC), and \>80% of these patients have different degrees of metastasis ([@b3-ol-0-0-10373]).

The most common sites for lung cancer metastasis are the nervous system, bone, liver, respiratory system and adrenal glands. Bone metastasis is the most common in patients with lung adenocarcinoma (39%) ([@b4-ol-0-0-10373]). The prognosis and survival rate of patients with advanced lung cancer are very poor, and the survival rate is not satisfactory. The median survival time of patients with stage IV NSCLC is 5 months ([@b5-ol-0-0-10373]). Patients with stage IV NSCLC with liver metastasis have the worst prognosis, \<3 months ([@b5-ol-0-0-10373]).

With advances in cancer treatment, molecular targeted therapy and immunotherapy may provide alternatives to the conventional surgery, radiotherapy and chemotherapy. However, targeted therapy is not effective in people without epidermal growth factor receptor (EGFR) mutations ([@b6-ol-0-0-10373]). The emergence of drug resistance in tumor cells may lead to treatment failure in a patient population that is suitable for targeted therapy ([@b7-ol-0-0-10373]). In addition, both targeted therapy and immunotherapy may be economically unfeasible for patients with lung cancer ([@b8-ol-0-0-10373],[@b9-ol-0-0-10373]). Accordingly, cost-effective treatment alternatives for patients with lung cancer are required.

The gold standard treatment for patients with NSCLC with distant metastasis is a multidisciplinary comprehensive treatment including chemoradiotherapy, immunotherapy, targeted therapy and immunotherapy rather than surgery. Furák *et al* ([@b10-ol-0-0-10373]) reported that the 5-year survival rate of patients with NSCLC that did not undergo surgical treatment was 5.8%. However, improvements in surgical techniques have improved the 5-year survival rate and median survival of patients with stage IV NSCLC ([@b11-ol-0-0-10373]--[@b13-ol-0-0-10373]). Therefore, surgical treatment in patients with stage IV NSCLC may be beneficial.

To date, there have been few large clinical retrospective studies on the surgical treatment of patients with stage IV NSCLC ([@b11-ol-0-0-10373],[@b12-ol-0-0-10373]). Accordingly, the current study aimed to investigate whether surgical treatment may improve the outcome of patients with stage IV NSCLC, as well as to identify the factors which influence the prognosis of patients. Relevant cases were selected from the Surveillance, Epidemiology, and End Results (SEER) (<https://seer.cancer.gov/>) program for further analysis.

Materials and methods
=====================

### Data collection

A total of 27,725 patients with stage IV NSCLC in the United States diagnosed between January 1, 2010 and December 31, 2013 with distinct metastatic sites in bone, brain, lung and liver and multiple metastases, that had received chemotherapy at least once, were selected from the SEER program. Patients included in this study were followed up between January 1, 2010 and November 31, 2016. Patients with incomplete or missing information were excluded. The distant metastatic lesions included only bone, brain, lung and liver. Other common sites, such as the pleura, adrenal gland and gastrointestinal tract were not included. The inclusion codes and criteria from the SEER database were are as follows: The primary tumor type was coded as lung (063), the coding of tumor pathological tissue classification was squamous cell neoplasms (02), and adenomas and adenocarcinomas (05). The following patient data were collected: i) Marital status; ii) ethnicity; iii) sex; iv) age at diagnosis; v) survival time (months); vi) overall survival (OS) and cancer-specific survival (CSS); vii) T stage; viii) N stage; ix) surgery of the primary site; x) surgery of the metastatic sites; xi) radiation therapy received; and xii) whether there was bone (not including the bone marrow), brain (not including the spinal cord or other parts of the central nervous system), lung (not including the pleura or pleural fluid) or liver metastasis. According to the SEER program definition, survival time means the time between diagnosis and death or the last follow-up time. OS is the time from the date of diagnosis to the death of any cause. CSS is the time from the date of diagnosis to the date of cancer-associated mortality. Surgery of the primary site describes a surgical procedure that removes and/or destroys tissue of the primary site performed as part of the therapy. Surgery of the metastatic sites describes the surgical removal of distant lymph node(s) or other tissue(s) or organ(s) beyond the primary site. According to the definition of the 7th Edition of the American Joint Committee on Cancer (AJCC) staging system ([@b14-ol-0-0-10373]), all the included patients with NSCLC were stage IV patients (T~0-4~N~0-3~M~1~), and the histopathological types included adenocarcinoma and squamous cell carcinoma. Patients with adenomas did not meet the above criteria and therefore were excluded from this study.

### Statistical analysis

The χ^2^ test was used to compare the clinicopathological features of the patients included in the study and determine whether there were differences between different metastatic lesions. The Kaplan-Meier method was used to estimate the survival function, and the differences were evaluated with the log-rank test by pair comparison. Multivariate Cox regression analysis was conducted to assess the association of specific factors that impact overall survival (OS) and CSS. Additionally, the 95% confidence interval (CI) for all hazard ratio (HRs) estimates across all strata were calculated. P\<0.05 was considered to indicate a statistically significant difference. All statistical operations were performed using SPSS software (version 22.0; IBM Corp., Armonk, NY, USA).

Results
=======

### Patient characteristics

A total of 27,725 patients with NSCLC in the United States diagnosed from January 1, 2010 to December 31, 2013 were included in the current study. A total of 17,603 patients had one metastatic lesion while 10,122 patients had ≥2 metastatic lesions. The number of patients with only bone, brain, lung and liver metastases was 5,989, 4,255, 5,717 and 1,642, respectively. The number of patients with two, three and four metastatic lesions was 7,275, 2,389 and 458 respectively. The mean age of the patients was 67.51 years, with a median of 68 years (range, 13--102 years). A total of 737, 1,761 and 146 patients received surgical intervention for their primary lesion only, metastatic lesion only and both primary and secondary lesions, respectively. However, the specific surgical intervention for each patient was not recorded. The basic information of the patients is presented in [Table I](#tI-ol-0-0-10373){ref-type="table"}.

### Survival outcomes

Survival analysis was performed to determine the OS of patients with the different isolated metastatic lesions. The median OS of patients with NSCLC with bone, brain, liver and lung metastases was 5, 6, 4 and 8 months, respectively. Patients with lung metastasis had an increased prognosis compared with the other patients (P\<0.001; [Fig. 1](#f1-ol-0-0-10373){ref-type="fig"}), while patients with liver metastasis had a decreased prognosis (P\<0.001; [Fig. 1](#f1-ol-0-0-10373){ref-type="fig"}). Significant differences of median OS time between patients with different organ metastasis were indicated.

In addition, the OS was also assessed based on the number of metastatic lesions. The median OS of patients with NSCLC with one, two, three or four metastatic sites was 6, 4, 3 and 3 months, respectively. Patients with one metastatic lesion had a significant increased prognosis compared with patients with \>1 metastatic lesion ([Fig. 2](#f2-ol-0-0-10373){ref-type="fig"}). Patients with two metastases had a significantly improved prognosis compared with patients with three and four metastases (two sites vs. three sites, P\<0.001; two sites vs. four sites, P\<0.001; [Fig. 2](#f2-ol-0-0-10373){ref-type="fig"}). However, there was no statistically significant difference in OS between patients with three and four metastatic lesions (P=0.721; [Fig. 2](#f2-ol-0-0-10373){ref-type="fig"}).

The patients with only bone, brain, liver, lung metastasis and patients with multiple metastases were divided into groups according to whether the primary or metastatic lesions were treated by surgery, and their OS was subsequently estimated. Patients with bone, brain, liver, lung metastasis and multiple metastatic lesions had a significantly increased prognosis following surgery on the primary lesions compared with patients who had not received surgery (bone, brain, liver, lung metastasis and multiple organ metastases, P\<0.001; [Fig. 3](#f3-ol-0-0-10373){ref-type="fig"}). Similarly, patients with only bone, brain, liver, lung metastasis and multiple metastatic lesions who received surgery on distant lesions had an improved OS compared with patients who had not received surgery (bone metastasis, P=0.043; lung metastasis, P=0.001; brain and multiple organ metastases, P\<0.001; [Fig. 4](#f4-ol-0-0-10373){ref-type="fig"}). There was a statistically significant difference in OS between patients who had underwent surgery and those who had not received surgery. However, there was no statistically significant difference in the median OS of patients with liver metastasis who had received surgery compared with patients who had not (P=0.388; [Fig. 4C](#f4-ol-0-0-10373){ref-type="fig"}).

Multivariate Cox proportional hazard models were used to determine the prognostic factors of patients with NSCLC with single and multiple organ metastases. The analysis in patients with single organ metastases revealed that patients with the following characteristics: i) Age (≤60); ii) sex (female); iii) tumor type (adenocarcinoma); iv) marital status (married); v) ethnicity (Asian); vi) N~0~ stage; vii) received surgery of the primary tumor (wedge resection and lobectomy) and metastatic lesion \[distant tissue(s) or organ(s)\]; and viii) received beam radiation therapy had improved OS and CSS compared with other patients ([Table II](#tII-ol-0-0-10373){ref-type="table"}). Using bone metastasis as a reference, patients with brain and liver metastases had a decreased OS (brain, HR, 1.162, 95% CI, 1.106--1.220; liver, HR, 1.081, 95% CI, 1.015--1.151), while patients with lung metastases had an improved OS (HR, 0.636; 95% CI, 0.607--0.667). The analysis in overall metastatic patient cohort revealed that patients with the following characteristics: i) Age (≤60); ii) sex (female); iii) tumor type (adenocarcinoma); iv) marital status (married); v) ethnicity (Asian); vi) N~0~ stage; vii) one metastatic lesion; viii) received surgery of the primary (wedge resection and lobectomy) and metastatic lesion (distant tissue(s) or organ(s)); and ix) received beam radiation therapy had improved OS and CSS ([Table III](#tIII-ol-0-0-10373){ref-type="table"}). Using single metastatic organ as a reference, patients with two, three and four metastases had a decreased OS (two metastases, HR, 1.336, 95% CI, 1.294--1.379; three metastases, HR, 1.649, 95% CI, 1.571--1.732; four metastases, HR, 1.787, 95% CI, 1.613--1.980) and CSS (two metastases, HR, 1.322, 95% CI, 1.275--1.372; three metastases, HR, 1.628, 95% CI, 1.541--1.721; four metastases, HR, 1.805, 95% CI, 1.613--2.019).

Discussion
==========

Improvements in lung cancer diagnosis and treatment have increased the 5-year survival rate and median survival time of patients with stage IV NSCLC ([@b15-ol-0-0-10373]). In recent years, an increased understanding of the genetic changes involved in lung cancer has led to molecular targeted therapy ([@b6-ol-0-0-10373]). Additionally, surgical techniques are also rapidly evolving ([@b16-ol-0-0-10373]). The emergence of radiofrequency ablation ([@b17-ol-0-0-10373]) and endoscopy ([@b18-ol-0-0-10373]) has contributed to the improved safety of surgical procedures. Individualized treatment plans may reduce the occurrence of adverse events and improve the quality of life of the patients ([@b19-ol-0-0-10373]).

The current study involved a retrospective analysis of a large population of patients with stage IV NSCLC selected from the SEER program. Compared with patients with other organ metastases, patients with lung metastasis had the longest OS, and patients with single organ metastasis had an increased OS compared with patients with multiple organ metastases. This suggested that the type and number of metastatic organs may affect the prognosis of patients with stage IV NSCLC. This is similar to previously published studies investigating bladder and colorectal cancer ([@b20-ol-0-0-10373],[@b21-ol-0-0-10373]). Furthermore, the current study established that surgical resection of the primary and metastatic organs may significantly improve the prognosis of patients with stage IV NSCLC.

The current study demonstrated that patients with only lung metastases had the best prognosis, patients with only brain metastases had a slightly improved prognosis compared with patients with only bone metastases, while those with liver metastases had the worst prognosis. Patients with only one metastasis had an improved prognosis compared with patients with multiple metastases. Previous studies have revealed similar results; patients with NSCLC and SCLC with liver metastasis and multiple metastases have the worst prognosis ([@b22-ol-0-0-10373]--[@b25-ol-0-0-10373]). Similar results were obtained using the AJCC staging system, where the number of metastatic organs had an effect on the prognosis of patients ([@b26-ol-0-0-10373]). Notably, the effect of the number of metastases is not same for different types of cancer, the OS of patients with pancreatic cancer is not affected by either single or multiple organ metastases ([@b27-ol-0-0-10373]). Pancreatic cancer is characterized by rapid growth, abundant pancreatic blood and lymphatic vessels, and incomplete pancreatic capsule. Therefore, the time of distant metastasis is relatively early, so whether there is distant metastasis or not, has little impact on OS ([@b28-ol-0-0-10373]).

Multivariate Cox regression analysis revealed that the prognosis of patients who underwent surgery for primary and metastatic lesions was better compared with patients who did not undergo the above. Surgical treatment remains the main approach used for the treatment of the majority of malignant tumors ([@b16-ol-0-0-10373]). Previously published studies revealed that certain patients with advanced NSCLC with unilateral contralateral lung metastasis, single brain, bone or adrenal metastasis may be treated surgically ([@b29-ol-0-0-10373]--[@b31-ol-0-0-10373]). For patients with NSCLC with isolated metastases and resectable pulmonary lesions, resection of the metastatic organs may also be considered. However, how isolated liver metastases should be removed remains unclear ([@b32-ol-0-0-10373]--[@b34-ol-0-0-10373]). Previous studies demonstrated that surgery serves an important role in the treatment of liver metastasis of neuroendocrine carcinoma and colorectal cancer, but not in lung cancer ([@b32-ol-0-0-10373],[@b35-ol-0-0-10373]). With advances in liver resection and the continuous improvement of surgical safety, previous case reports described surgical resection of liver metastatic carcinoma with satisfactory results ([@b33-ol-0-0-10373],[@b34-ol-0-0-10373]).

The benefit of surgical treatment on the prognosis of patients with advanced lung cancer remains controversial ([@b29-ol-0-0-10373]--[@b32-ol-0-0-10373]). A previous study based on SEER program analysis suggested that no further surgical treatment is recommended for patients with advanced lung cancer ([@b36-ol-0-0-10373]). However, additional studies do not concur with this recommendation ([@b37-ol-0-0-10373]). Patients with stage IV NSCLC who received pneumonectomy and thoracic wall enlargement resection had an improved quality of life and 5-year survival ([@b38-ol-0-0-10373]). However, this is contrary to what was observed in the current study. Results from a previous study suggested that the long-term survival rate of patients is related to the degree of tumor infiltration into the chest wall, and thus the scope of resection should be determined according to the degree of infiltration ([@b39-ol-0-0-10373]). Using the SEER program, previous studies have revealed that the size of the lung cancer lesions should guide the choice of surgical intervention and expanding the scope of surgical resection will not improve prognosis ([@b40-ol-0-0-10373]). A previous study revealed that lymph node dissection for distant metastatic lesions is necessary to improve the prognosis ([@b41-ol-0-0-10373]). Taken together, the results from the aforementioned studies suggest that it is important to identify specific patients who may benefit from surgical procedures.

Radiotherapy is widely used for patients with advanced lung cancer ([@b42-ol-0-0-10373]). A previous study revealed that surgery following radiotherapy may be beneficial to patients ([@b43-ol-0-0-10373]). The most commonly employed method of radiotherapy is beam radiation ([@b44-ol-0-0-10373]), which was consistent with the results obtained in the current study. However, previous studies reported that radioactive implants and radioisotopes may offer promising results for patients with advanced NSCLC ([@b45-ol-0-0-10373],[@b46-ol-0-0-10373]).

Multivariate Cox regression analysis revealed that age, sex, marital status, ethnicity, N stage and tumor type affected the prognosis of patients with NSCLC in the current study. Patients \>60 years had an improved prognosis compared with other patients. Toffart *et al* ([@b47-ol-0-0-10373]) revealed that patients with NSCLC \>63 years had significantly decreased OS compared with other younger patients using a multivariate cox analysis (HR=1.63; 95% CI: 1.013--2.63; P=0.04). The current study demonstrated that the prognosis of female patients was improved compared with male patient. This may be attributed to different hormone and corresponding receptor expression levels ([@b48-ol-0-0-10373]). In terms of marital status, previous large epidemiological studies revealed that marriage benefits patients with less aggressive cancer ([@b49-ol-0-0-10373],[@b50-ol-0-0-10373]), which is consistent with the results obtained in the current study. The effect of ethnicity on the prognosis of patients with NSCLC patients remains controversial ([@b51-ol-0-0-10373]--[@b54-ol-0-0-10373]). A previous study revealed that African-Americans with lung cancer had a decreased 5-year survival rate compared with Caucasians ([@b51-ol-0-0-10373]). Similar survival rates for African-Americans and Caucasians have been reported for patients with lung cancer ([@b52-ol-0-0-10373],[@b53-ol-0-0-10373]). Tannenbaum *et al* ([@b54-ol-0-0-10373]) reported that Asian patients with NSCLC had significantly increased survival rates compared with Caucasian patients, which is consistent with the results obtained in the current study.

The results obtained in the current study suggested that there was no statistical difference in the prognosis of patients with different T stages. This is not in accordance with the AJCC staging system. However, the patients selected in the current study all had stage IV NSCLC, according to the 7 Edition of the AJCC staging system with only four sites of metastases identified, and may not conform with the principles of the staging system, due to a limited representative sample. The current study revealed that the N stage influenced the prognosis of patients with stage IV NSCLC. This was consistent with a previous study which suggested that lymph node metastasis is an adverse prognostic factor for the surgical treatment of patients with advanced NSCLC ([@b55-ol-0-0-10373]). The aforementioned study recommended that patients with N~0~ stage should be eligible for surgical treatment and that surgery for patients with extensive lymph node metastases may not be beneficial ([@b55-ol-0-0-10373]). There are few studies investigating the prognosis of patients with stage IV NSCLC with adenocarcinoma and squamous carcinoma ([@b56-ol-0-0-10373],[@b57-ol-0-0-10373]). A retrospective study of 148 Chinese patients with NSCLC revealed that non-lung adenocarcinoma was a prognostic risk factor in patients with NSCLC ([@b57-ol-0-0-10373]), consistent with the results obtained in the current study.

The present study had certain limitations. Firstly, due to the retrospective nature of the study, confounding factors, such as smoking history and age, were not easily excluded. Secondly, the specific chemotherapy regimens and radiation doses were not detailed in the SEER program, and these may have had an impact on the prognosis of the patients ([@b58-ol-0-0-10373]). Thirdly, the SEER program did not include data on whether the patients were treated with tyrosine kinase inhibitors, due to EGFR mutations being more prevalent in non-smoking, female, Asian patients ([@b59-ol-0-0-10373]). The OS would be affected if they were treated with tyrosine kinase inhibitors ([@b6-ol-0-0-10373]), influencing our conclusions. Finally, more distal metastases, such as in the adrenal gland and gastrointestinal tract, cannot be included without relevant data, and at the same time, the sequence of metastatic lesions cannot be determined. The results obtained in the current study require further examination by future well-designed studies to validate this study\'s results.
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###### 

Clinicopathological characteristics of patients with metastatic non-small cell lung cancer.

  Variable                                        Bone metastasis   Brain metastasis   Liver metastasis   Lung metastasis   Multiple metastasis   χ^2^ value   P-value
  ----------------------------------------------- ----------------- ------------------ ------------------ ----------------- --------------------- ------------ ----------
  Age at diagnosis                                                                                                                                             
    ≤60                                           1,483             1,493              335                1,101             3,087                 5,842.255    \<0.001
    \>60                                          4,506             2,762              1,307              4,616             7,035                              
  Sex                                                                                                                                                          
    Female                                        2,417             2,021              692                2,684             4,517                 3,38.394     \<0.001
    Male                                          3,572             2,234              950                3,033             5,605                              
  Tumor type                                                                                                                                                   
    Squamous cell                                 1,569             838                603                1,958             1,934                 6,989.873    \<0.001
    carcinomas                                                                                                                                                 
    Adenocarcinoma                                4,420             3,417              1,039              3,759             8,188                              
  Marital status                                                                                                                                               
    Unmarried                                     2,643             2,042              783                2,820             4,462                 178.562      \<0.001
    Married                                       3,346             2,231              859                2,897             5,660                              
  Ethnicity                                                                                                                                                    
    Caucasian                                     4,879             3,391              1,338              4,513             7,860                 44,453.648   \<0.001
    African-American                              716               573                214                759               1,284                              
    Asian                                         387               282                83                 432               948                                
    Australoid                                    7                 9                  7                  13                30                                 
  T stage                                                                                                                                                      
    0                                             72                66                 28                 9                 50                    11,588.136   \<0.001
    1                                             1,068             780                245                241               782                                
    2                                             1,871             1,452              490                665               1,808                              
    3                                             1,441             996                420                1,687             2,962                              
    4                                             1,537             991                459                3,115             4,520                              
  N stage                                                                                                                                                      
    0                                             1,637             1,253              475                1,646             1,827                 8,358.724    \<0.001
    1                                             616               424                145                349               764                                
    2                                             2,755             1,931              778                2,351             5,036                              
    3                                             984               647                244                1,371             2,495                              
  Surgery of the primary site                                                                                                                                  
    No                                            5,847             4,006              1,596              5,403             9,990                 76,277.022   \<0.001
    Wedge resection                               75                84                 27                 200               105                                
    Lobectomy                                     59                156                18                 102               24                                 
    Pneumonectomy                                 8                 9                  1                  12                3                                  
  Surgery of the metastases                                                                                                                                    
    No                                            5,695             3,385              1,612              5,610             9,516                 92,989.834   P\<0.001
    Surgical procedure to other regional sites    25                16                 6                  27                26                                 
    Surgical procedure to distant lymph node(s)   24                26                 3                  20                51                                 
    Surgical procedure to distant site            241               827                21                 56                519                                
    Combination of all the above                  4                 1                  0                  4                 10                                 
  Radiation therapy                                                                                                                                            
    No                                            2,755             775                1,351              4,346             4,303                 41,417.869   P\<0.001
    Beam radiation                                3,226             3,476              289                1,362             5,801                              
    Radioactive implants                          3                 3                  0                  4                 3                                  
    Radioisotopes                                 2                 0                  1                  1                 6                                  
    Combination of 2 or                           3                 1                  1                  4                 9                                  

3 above

###### 

Multivariate Cox regression analysis for OS and CSS in patients with a single metastatic site.

                                                  OS                     CSS                              
  ----------------------------------------------- ---------------------- --------- ---------------------- ---------
  Age at diagnosis                                                                                        
    ≤60                                           1.00 (reference)                 1.00 (reference)       
    \>60                                          1.017 (1.015--1.019)   \<0.001   1.017 (1.015--1.019)   \<0.001
  Sex                                                                                                     
    Female                                        1.00 (reference)                 1.00 (reference)       
    Male                                          1.291 (1.244--1.338)   \<0.001   1.275 (1.222--1.330)   \<0.001
  Tumor type                                                                                              
    Squamous cell                                 1.00 (reference)                 1.00 (reference)       
    carcinomas                                                                                            
    Adenocarcinoma                                0.930 (0.918--0.942)   \<0.001   0.921 (0.907--0.935)   \<0.001
  Marital status                                                                                          
    Unmarried                                     1.00 (reference)                 1.00 (reference)       
    Married                                       0.841 (0.812--0.872)   \<0.001   0.831 (0.797--0.866)   \<0.001
  Ethnicity                                                                                               
    Caucasian                                     1.00 (reference)                 1.00 (reference)       
    African-American                              1.000 (0.949--1.053)   0.991     1.022 (0.963--1.085)   0.471
    Asian                                         0.674 (0.625--0.728)   \<0.001   0.669 (0.614--0.730)   \<0.001
    Australoid                                    0.717 (0.457--1.125)   0.148     0.709 (0.427--1.178)   0.185
  T stage                                                                                                 
    0                                             1.00 (reference)                 1.00 (reference)       
    1                                             0.781 (0.654--0.932)   0.006     0.845 (0.689--1.035)   0.104
    2                                             0.888 (0.746--1.057)   0.181     0.954 (0.781--1.165)   0.642
    3                                             1.008 (0.847--1.200)   0.931     1.090 (0.893--1.332)   0.396
    4                                             1.042 (0.861--1.219)   0.787     1.119 (0.917--1.366)   0.268
  N stage                                                                                                 
    0                                             1.00 (reference)                 1.00 (reference)       
    1                                             1.134 (1.059--1.214)   \<0.001   1.114 (1.029--1.207)   0.008
    2                                             1.276 (1.222--1.332)   \<0.001   1.237 (1.176--1.302)   \<0.001
    3                                             1.340 (1.271--1.413)   \<0.001   1.314 (1.235--1.398)   \<0.001
  Surgery of the primary                                                                                  
    No                                            1.00 (reference)                 1.00 (reference)       
    Wedge resection                               0.718 (0.630--0.819)   \<0.001   0.687 (0.586--0.805)   \<0.001
    Lobectomy                                     0.361 (0.305--0.428)   \<0.001   0.346 (0.281--0.426)   \<0.001
    Pneumonectomy                                 0.791 (0.525--1.191)   0.262     0.840 (0.535--1.319)   0.449
  Surgery of the metastases                                                                               
    No                                            1.00 (reference)                 1.00 (reference)       
    Surgical procedure to other regional sites    0.843 (0.634--1.120)   0.237     0.786 (0.572--1.082)   0.140
    Surgical procedure to distant lymph node(s)   0.806 (0.605--1.075)   0.142     0.796 (0.571--1.112)   0.181
    Surgical procedure to distant site            0.778 (0.720--0.841)   \<0.001   0.768 (0.704--0.838)   \<0.001
    Combination of all the above                  1.402 (0.629--3.126)   0.409     1.419 (0.636--3.166)   0.393
  Radiation therapy                                                                                       
    No                                            1.00 (reference)                 1.00 (reference)       
    Beam radiation                                0.808 (0.776--0.841)   \<0.001   0.823 (0.786--0.863)   \<0.001
    Radioactive implants                          1.616 (0.769--3.396)   0.205     1.315 (0.423--4.803)   0.636
    Radioisotopes                                 1.317 (0.494--3.512)   0.582     1.264 (0.407--3.923)   0.685
    Combination of 2 or 3 above                   0.958 (0.430--2.135)   0.916     0.987 (0.410--2.377)   0.976
  Metastatic site                                                                                         
    Bone only                                     1.00 (reference)                 1.00 (reference)       
    Brain only                                    1.162 (1.106--1.220)   \<0.001   1.131 (1.070--1.197)   \<0.001
    Liver only                                    1.081 (1.015--1.151)   0.016     1.075 (0.999--1.157)   0.053
    Lung only                                     0.636 (0.607--0.667)   \<0.001   0.635 (0.600--0.671)   \<0.001

OS, overall survival; CSS, cancer-specific survival; HR, hazard ratio; CI, confidence interval.

###### 

Multivariate Cox regression analysis for OS and CSS in overall metastatic patient cohort.

                                                  OS                     CSS                              
  ----------------------------------------------- ---------------------- --------- ---------------------- ---------
  Age at diagnosis                                                                                        
    ≤60                                           1.00 (reference)                 1.00 (reference)       
    \>60                                          1.269 (1.229--1.310)   \<0.001   1.275 (1.231--1.321)   \<0.001
  Sex                                                                                                     
    Female                                        1.00 (reference)                 1.00 (reference)       
    Male                                          1.287 (1.251--1.324)   \<0.001   1.281 (1.240--1.323)   \<0.001
  Tumor types                                                                                             
    Squamous cell carcinomas                      1.00 (reference)                 1.00 (reference)       
    Adenocarcinoma                                0.930 (0.920--0.940)   \<0.001   0.920 (0.909--0.931)   \<0.001
  Marital status                                                                                          
    Unmarried                                     1.00 (reference)                 1.00 (reference)       
    Married                                       0.834 (0.811--0.857)   \<0.001   0.823 (0.797--0.849)   \<0.001
  Ethnicity                                                                                               
    Caucasian                                     1.00 (reference)                 1.00 (reference)       
    African-American                              0.964 (0.825--1.004)   0.074     0.981 (0.937--1.028)   0.421
    Asian                                         0.658 (0.622--0.696)   \<0.001   0.655 (0.616--0.697)   \<0.001
    Australoid                                    0.745 (0.544--1.021)   0.067     0.721 (0.507--1.026)   0.069
  T stage                                                                                                 
    0                                             1.00 (reference)                 1.00 (reference)       
    1                                             0.756 (0.649--0.882)   \<0.001   0.831 (0.697--0.990)   0.039
    2                                             0.850 (0.732--0.988)   0.034     0.928 (0.781--1.102)   0.393
    3                                             0.874 (0.753--1.016)   0.079     0.964 (0.812--1.145)   0.675
    4                                             0.842 (0.725--0.978)   0.024     0.933 (0.787--1.107)   0.430
  N stage                                                                                                 
    0                                             1.00 (reference)                 1.00 (reference)       
    1                                             1.129 (1.069--1.193)   \<0.001   1.122 (1.052--1.196)   \<0.001
    2                                             1.231 (1.188--1.274)   \<0.001   1.190 (1.143--1.240)   \<0.001
    3                                             1.194 (1.145--1.245)   \<0.001   1.175 (1.120--1.234)   \<0.001
  Surgery of the primary                                                                                  
    No                                            1.00 (reference)                 1.00 (reference)       
    Wedge resection                               0.670 (0.598--0.750)   \<0.001   0.670 (0.587--0.765)   \<0.001
    Lobectomy                                     0.362 (0.308--0.424)   \<0.001   0.349 (0.287--0.425)   \<0.001
    Pneumonectomy                                 0.720 (0.486--1.066)   0.101     0.774 (0.504--1.188)   0.242
  Surgery of the metastases                                                                               
    No                                            1.00 (reference)                 1.00 (reference)       
    Surgical procedure to other regional sites    0.857 (0.676--1.086)   0.202     0.836 (0.638--1.096)   0.194
    Surgical procedure to distant lymph node(s)   0.883 (0.713--1.093)   0.252     0.875 (0.686--1.118)   0.286
    Surgical procedure to distant site            0.852 (0.802--0.906)   \<0.001   0.829 (0.775--0.888)   \<0.001
    Combination of all the above                  1.021 (0.604--1.726)   0.938     0.984 (0.570--1.697)   0.952
  Radiation therapy                                                                                       
    No                                            1.00 (reference)                 1.00 (reference)       
    Beam radiation                                0.881 (0.856--0.906)   \<0.001   0.892 (0.864--0.921)   \<0.001
    Radioactive implants                          1.498 (0.805--2.786)   0.202     1.302 (0.585--2.901)   0.518
    Radioisotopes                                 0.646 (0.308--1.335)   0.248     0.613 (0.255--1.475)   0.275
    Combination of 2 or 3 above                   0.821 (0.454--1.484)   0.513     1.051 (0.565--1.958)   0.874
  Number of metastatic sites                                                                              
    Single                                        1.00 (reference)                 1.00 (reference)       
    Double                                        1.336 (1.294--1.379)   \<0.001   1.322 (1.275--1.372)   \<0.001
    Triple                                        1.649 (1.571--1.732)   \<0.001   1.628 (1.541--1.721)   \<0.001
    Four                                          1.787 (1.613--1.980)   \<0.001   1.805 (1.613--2.019)   \<0.001

OS, overall survival; CSS, cancer-specific survival; HR, hazard ratio; CI, confidence interval.
